Contingent Consideration (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of Reconciliation of Contingent Consideration Liability

The following table represents a reconciliation of the contingent consideration liability related to the acquisition of QuaDPharma in 2014 measured on a recurring basis using level 3 inputs as of December 31, 2016 (in thousands):

Balance as of December 31, 2015	$	1,133
Adjustment to fair value		(106	)
Satisfied through issuance of common stock		(343	)
Paid in cash		(684	)
Balance as of December 31, 2016	$	—

The following table represents a reconciliation of the contingent consideration liability related to the acquisition of Polymed measured on a recurring basis using level 3 inputs as of December 31, 2016:

Balance as of December 31, 2015	$	4,841
Adjustment to fair value		159
Satisfied through issuance of common stock		(2,500	)
Paid in cash		(2,500	)
Balance as of December 31, 2016	$	—